Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN …
J Guigay, J Fayette, A Dillies, C Sire… - Journal of Clinical …, 2011 - ascopubs.org
5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN …
J Guigay, J Fayette, AF Dillies, C Sire, JN Kerger… - 2012 - ascopubs.org
5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
[HTML][HTML] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter …
J Guigay, J Fayette, AF Dillies, C Sire, JN Kerger… - Annals of …, 2015 - Elsevier
Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …
Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer
M Knoedler, TC Gauler, A Matzdorff, A Dietz… - Journal of Clinical …, 2008 - ascopubs.org
6066 Background: Treatment options for patients with squamous cell cancer of the head and
neck (SCCHN) are limited. Cetuximab, an antiepidermal growth factor receptor monoclonal …
neck (SCCHN) are limited. Cetuximab, an antiepidermal growth factor receptor monoclonal …
Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab …
J Guigay, E Chamorey, G Lefebvre, M Rotarski… - Cancer …, 2022 - Wiley Online Library
Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …
[HTML][HTML] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic …
P Bossi, R Miceli, LD Locati, D Ferrari, S Vecchio… - Annals of …, 2017 - Elsevier
Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
[HTML][HTML] The observational ENCORE study: cetuximab+ platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell …
C Le Tourneau, M Ghiani, MC Cau… - Annals of …, 2017 - annalsofoncology.org
Background: The randomized, phase 3 EXTREME study established cetuximab+ platinum+
5-flurouracil (5-FU) followed by cetuximab maintenance until progressive disease (PD) as …
5-flurouracil (5-FU) followed by cetuximab maintenance until progressive disease (PD) as …
[HTML][HTML] Cetuximab+ platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck …
C Le Tourneau, M Ghiani, MC Cau… - Annals of …, 2018 - annalsofoncology.org
Background: The EXTREME regimen (cetuximab+ PBT≤ 6 cycles followed by cetuximab-
alone maintenance until progressive disease [PD]) was the first treatment in 30 years to …
alone maintenance until progressive disease [PD]) was the first treatment in 30 years to …
Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies
JB Vermorken, J Bourhis, J Trigo, M Kies… - Journal of Clinical …, 2005 - ascopubs.org
5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …
Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up …
JB Vermorken, E Remenar, R Hitt, A Kawecki, S Rottey… - 2014 - ascopubs.org
6021^ Background: The EXTREME trial demonstrated that patients with R/M-SCCHN benefit
significantly from the addition of cetuximab to first-line platinum-based CT in relation to …
significantly from the addition of cetuximab to first-line platinum-based CT in relation to …